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opic.– New techniques of rehabilitation and assessment (TBC).
bjectives.– To describe rehabilitation goals and attainment of upper (UL) and
ower limb (LL) function in focal PSS patients, using goal attainment scaling.
ethods.– Subjects were randomised to Botox® (BoNT-A) + standard care (SC)
r placebo + SC for up to 2 treatment cycles, followed by an open-label phase
p to a total of 52 weeks. Eligible patients were BoNT-A naïve, demonstrated
reserved function in the limb to be treated, and were considered likely to benefit
rom the intervention. For each patient, a principal active functional goal was
efined as well as a secondary active or passive goal and the principal goal
ttainment was measured at the end of the randomised period.
esults.– The intent-to-treat population comprised 273 patients recruited in
anada, Germany, Sweden and the UK (59% male; mean age: 61.5 years; median
ime since stroke: 22.8 months). In total, 165 patients had a principal or secondary
ctive goal concerning UL function (respectively 116 and 49), 222 patients had
ither a principal or secondary active goal concerning LL function (respectively
57 and 65), and 158 patients had a secondary passive goal.
or patients with an active goal pertained to UL function, the main goal categories
ere: ability to grasp and hold objects with either gross or fine movements
31.5%), feeding (23.6%), dressing (16.4%), and improved upper limb range
f movement (12.7%). For those patients whose principal active goal pertained
o LL function, most were associated with walking/mobility (89.2%) including
mprovements in speed, distance, gait and ability to climb stairs.
ctive goals pertaining to UL were achieved by 39.5% of patients receiving
oNT-A + SC and 30.7% of patients receiving placebo + SC and active LL
oals were achieved by 41.9% of patients receiving BoNT-A + SC and 45.1%
f patients receiving placebo + SC. Secondary passive goals were achieved by
0.6% of the patients receiving BoNT-A + SC and 38.6% of patients receiving
lacebo + SC.
onclusion.– More patients treated with Botox® + SC achieved their UL active
oals and passive goals compared to placebo + SC.
oi:10.1016/j.rehab.2011.07.564
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disabling ﬁnger ﬂexor spasticity six months later
. Werner a,∗, H. Mach b, I. Melzer c, S. Hesse d
Charité, University Medicine Berlin, Medical Park Berlin, An der Mühle 2-9,
3507 Berlin, Germany
Fachklinik Schwaan Waldeck, Schwaan, Germany
Medical Park Berlin, Berlin, Germany
Medical Park Berlin, Charité, University Medicine Berlin, Berlin, Germany
Corresponding author.
eywords: Spasticity; Hemiparesis; Stroke; Botulinum toxin
bjective.– The study asked whether an early BTX-A injection in sub-acute
troke patients may prevent a disabling finger flexor spasticity six months later.
esign.– A single-blind, randomized pilot study.
etting.– In-patient rehabilitation centre.
ubjects.– Eighteen stroke patients, interval 4–6 weeks, non-functional upper
imb (UL), Fugl-Meyer UL score (FM, 0–66) < 20, beginning finger flexor spas-
icity, randomly allocated to group A or B.
nterventions.– In A-patients 150 units BTX-A (Xeomin) injected into the deep
nd superficial finger (100 units) and wrist flexors (50 units), no injection in
-patients. Comprehensive rehabilitation in both groups.
ain measures.– Primary variable was the modified Ashworth score (AS, 0–5)
f the finger flexors, secondary the whole UL tonus with the REPAS, the UL
otor control with the FM, and a disability scale, blindly assessed at T0 (begin),
1 (4 weeks) and T6 (6 months).
esults.– Homogeneous groups at T0. Significantly less finger flexor tonus in
he BTX-A group at T1 and T6, the mean (SD) AS scores in group A (B) were:
.7 ± 0.5, (1.6 ± 0.5) at T0; 0.4 ± 0.5 (1.9 ± 0.7) at T1; and 1.4 ± 0.7 (2,4 ± 0.9)
a
a
R
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t T6. Among the secondary, the disability score, namely the items pain and
assive nail trimming, was less in group A at T1 and T6.
onclusions.– The pilot character prohibits any conclusions, but the results indi-
ate a prohibitive effect of an early BTX-A injection on finger flexor spasticity
ix months later. By minimizing involuntary muscle activity, the fingers were
eld in a less fixed position, which may have hindered contractures, usually
apidly developing.
oi:10.1016/j.rehab.2011.07.565
O16-007–EN
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bjective.– To test the validity and reliability of a subjective questionnaire
or evaluation of spasticity during daytime, sleep and activities of daily living
ADL).
ubjects and methods.– Our sample consisted of 50 subjects (30 male) with
ean age 48.2 ± 15.3 years (ranging from 21 to 84 years). The questionnaire
as constructed based on the functional classification of disability according to
HO. (2001) and it is self-administered. It consists of 12 domains (Likert scale)
or evaluation of the effect of pain, involuntary movement and spasticity on ADL
uch sleep quality, hygiene, routine activities, social life, driving, orthosis wear
nd gait. Reliability was tested via Cronbach’s  coefficient. The item discrimi-
ant validity test was performed according to the severity of complaints based
n clinical evaluation of spasticity via modified Asworth scale. The construct
alidity was tested via item-scale correlations.
esults.– More than half of the patients reported that spasticity, accompa-
ying pain and involuntary movements were getting more intense during night.
edium to severe spasticity, accompanying pain and involuntary movements
ere reported by 80.4%, 52.9% and 60% of the subjects, respectively. Most of
he complaints were noted during walking. Internal consistency was measured
y Cronbach’s , which was found 0.96 for questions concerning pain, 0.98
or questions concerning involuntary movements and 0.97 for spasticity. The
ore severe the clinical grade of spasticity, the more troublesome complaints
ere reported by the patients in a number of questions. The Pearson correlation
oefficients ranged mostly from medium (r > 0.4) to high (r > 0.6), indicating
edium to high reproducible scales, respectively.
onclusion.– The questionnaire is a promising, new instrument for evaluation of
he subjective feeling of spasticity during night and ADL. It comes up forward
o fill in the gap in the field of spasticity and it is useful for recording the
ffectiveness of spasticity treatment outcome and rehabilitation program.
oi:10.1016/j.rehab.2011.07.566
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troke is the leading cause of disability for adults in France. After stroke, equi-
ovarus foot is the main cause of gait abnormalities. The efficiency of botulinum
oxin in decreasing spasticity has been demonstrated but the effects on gait para-
eters (gait velocity. . .) are still conflicting. The purpose of this study was to
valuate the effects of an injection of botulinum toxin type A, compared with
lacebo, on gait parameters.
ethods.– This was a multicenter, randomised, double-blind, versus placebo
tudy. To be included, patients had to suffer from a hemiplegia with an equi-
ovarus foot due to stroke. A medical examination (physical examination, gait
nalysis using a GAITRite® system. . .) was performed before and 4 to 6 weeks
fter the injection.
esults.– We included 49 patients, randomised in two groups: treatment with
otulinum toxin type A (n = 23) and placebo (n = 26). No significant difference
